Principal Investigator
Marco Armando, MD, PhD
Bambino Gesù Hospital and Research Institute
Total Trials
1
As PI
1
Completed
0
h-index
N/A
Publications
0
Years Active
0
Research Impact
h-index
N/A
Research impact score
Publications
0
Total publications
Trial Results
0
Published trial results
Citations
0
Total citations
Drug Portfolio
DIETARY_SUPPLEMENT(1)
MIXED(1)
Standard care
1 trial
phase_2_3
bambino-gesù-hospital-and-research-instituteomega-3 PUFAs
1 trial
phase_2_3
bambino-gesù-hospital-and-research-institute2 unique interventions2 categories
Analytics
Trial Phases
Phase 21
Phase 31
Trial Status
Other1
Role Distribution
Principal Investigator1
PI Rate100%
Activity Timeline
Clinical Trials (1)
Indicated Prevention With Long-chain Polyunsaturated Omega-3 Fatty Acids in Patients With 22q11 Microdeletion Syndrome.
22q11 Deletion Syndrome
Principalinvestigator
Research Network
Collaboration Network
1 collaborators·0 connections
Network Legend
KOL
Current InvestigatorCO
High-influence CollaboratorCO
CollaboratorClick: view details
Double-click: go to profile
Drag: move node
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Bambino Gesù Hospital and Research Institute
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
4 similar investigators found
Alison Parker, PhD
Innovation Research & Training
6 trials
Shared therapeutic areas:
22q11 Deletion Syndrome
Similarity Score30%
Mary Norton, MD
University of California, San Francisco
7 trials
Shared therapeutic areas:
22q11 Deletion Syndrome
Similarity Score30%
Dr. Evdokia Anagnostou
Holland Bloorview Kids Rehab Hospital
1 trials
Shared therapeutic areas:
22q11 Deletion Syndrome
Similarity Score30%
Peer Dar, MD
Montefiore Medical Center
2 trials
Shared therapeutic areas:
22q11 Deletion Syndrome
Similarity Score30%
Publications (0)
No publications found for this investigator.
Clinical Trials (1)
Showing 1 of 1 trials
Indicated Prevention With Long-chain Polyunsaturated Omega-3 Fatty Acids in Patients With 22q11 Microdeletion Syndrome.
22q11 Deletion Syndrome
All 1 trials loaded